🧪
hypothesis

Temporal Gating Through HSP70 ATPase Cycle Manipulation

Hypothesis

Temporal Gating Through HSP70 ATPase Cycle Manipulation

Compounds that extend HSP70's ATPase cycle specifically when bound to tau substrates, trapping tau in non-productive chaperone complexes and leading to tau sequestration and degradation through quality control pathways.
🧬 HSPA1A🩺 drug-discovery🎯 Composite 46%💱 $0.52▲5.2%active
drug discovery
EvidencePending (0%)📖 5 cit🗣 1 debates 5 support 1 oppose
✓ All Quality Gates Passed
Mechanistic 0.50 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.50 (10%) Safety 0.50 (8%) Competition 0.50 (6%) Data Avail. 0.50 (5%) Reproducible 0.50 (5%) KG Connect 0.12 (8%) 0.455 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite46%

🧪 Overview

Compounds that extend HSP70's ATPase cycle specifically when bound to tau substrates, trapping tau in non-productive chaperone complexes and leading to tau sequestration and degradation through quality control pathways.

🧬 Mechanism

🔗 Mechanism from KG for HSPA1A

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    HSPA1A["HSPA1A"] -->|protein interactio| STUB1["STUB1"]
    MAPT["MAPT"] -->|regulates| HSPA1A_1["HSPA1A"]
    Bifunctional_PROTACs["Bifunctional PROTACs"] -->|targets| HSPA1A_2["HSPA1A"]
    HSPA1A_3["HSPA1A"] -->|regulates| tau_protein["tau protein"]
    HSPA1A_4["HSPA1A"] -->|regulates| proteasomal_degradation_p["proteasomal degradation pathway"]
    style HSPA1A fill:#ce93d8,stroke:#333,color:#000
    style STUB1 fill:#ce93d8,stroke:#333,color:#000
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style HSPA1A_1 fill:#ce93d8,stroke:#333,color:#000
    style Bifunctional_PROTACs fill:#4fc3f7,stroke:#333,color:#000
    style HSPA1A_2 fill:#4fc3f7,stroke:#333,color:#000
    style HSPA1A_3 fill:#4fc3f7,stroke:#333,color:#000
    style tau_protein fill:#4fc3f7,stroke:#333,color:#000
    style HSPA1A_4 fill:#4fc3f7,stroke:#333,color:#000
    style proteasomal_degradation_p fill:#81c784,stroke:#333,color:#000

⚖️ Evidence

⚖️ Evidence Matrix5 supports1 contradicts
Supports
Folding or holding?-Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease.
J Biol Chem2022PMID:35398094medium
Supports
DnaJC7 specifically regulates tau seeding.
Elife2023PMID:37387473medium
Supports
DnaJC7 specifically regulates tau seeding.
bioRxiv2023PMID:36993367medium
Supports
The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system.
Nat Commun2023PMID:36732333medium
Supports
Mechanism of Tau protein incorporation into exosomes via cooperative recognition of KFERQ-like motifs by LAMP2A and HSP70.
Neurochem Int2025PMID:40187566medium
Contradicts
From sleep to cancer to neurodegenerative disease: the crucial role of Hsp70 in maintaining cellular homeostasis and potential therapeutic implications.
J Biomol Struct Dyn2024PMID:37643058medium
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — HSPA1A

🧬 PDB 4B9Q Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HSPA1A →

No DepMap CRISPR Chronos data found for HSPA1A.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0511
Events (7d)
0
Price History
▲5.2%

💾 Resource Usage

LLM Tokens
18,738
$0.1124
Total Cost
$0.1124

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF HSPA1A ATPase inhibition (15 μM PES) is applied to iPSC-derived cortical neurons from a PSP patient cohort for 48 hours, THEN total tau protein will be reduced by >50% relative to vehicle controls,>50% reduction in total tau (normalized to βIII-tubulin loading control) in treatment vs. control; reversal of effect with bortezomib co-treatment.— no observation —pending0.58
IF HSPA1A ATPase activity is selectively inhibited (e.g., 2-phenylethynesulfonamide at 20 μM) in human neuroglioma cells overexpressing 2N4R tau for 24 hours, THEN tau-HSPA1A complex abundance will inIncreased tau-HSPA1A complex formation (+>100%) and reduced soluble tau concentration (-40%), both quantified by co-immunoprecipitation and quantitative western— no observation —pending0.62
🔮 Falsifiable Predictions (2)
pendingconf 62%
IF HSPA1A ATPase activity is selectively inhibited (e.g., 2-phenylethynesulfonamide at 20 μM) in human neuroglioma cells overexpressing 2N4R tau for 24 hours, THEN tau-HSPA1A complex abundance will increase >2-fold and free cytosolic tau will decrease >40% compared to DMSO-treated controls, because
Predicted outcome: Increased tau-HSPA1A complex formation (+>100%) and reduced soluble tau concentration (-40%), both quantified by co-immunoprecipitation and quantitati
Falsification: No significant change in tau-HSPA1A complex abundance (<20% increase) or tau levels unchanged/increased after ATPase inhibition would disprove the mechanism.
pendingconf 58%
IF HSPA1A ATPase inhibition (15 μM PES) is applied to iPSC-derived cortical neurons from a PSP patient cohort for 48 hours, THEN total tau protein will be reduced by >50% relative to vehicle controls, and this effect will be completely abolished by co-treatment with proteasome inhibitor bortezomib (
Predicted outcome: >50% reduction in total tau (normalized to βIII-tubulin loading control) in treatment vs. control; reversal of effect with bortezomib co-treatment.
Falsification: Bortezomib fails to block tau reduction, or tau levels do not decrease >30% despite ATPase inhibition, would indicate HSP70-independent mechanism.
View on SciDEX ↗